PD-1/PD-L1 axis is the most studied IC pathway in AML (153), and PD-L1 expression on AML blasts were reported to be linked with the inflamed tumor microenvironment, highlighting the potential of targeting BMM in disease management (154, 155). The gene discussed is CD274; the disease is acute myeloid leukemia.